Assignee
ELEVAID THERAPEUTICS INC
US·2 granted patents·2 pending applications·0 citations·filing 2022–2025
Top patents by PatentIndex Score
4 records- 0180US12102605B2Use of atovaquone and proguanil for treatment of gastrointestinal diseases and inflammationELEVAID THERAPEUTICS INC·Filed 2024·Granted Oct 1, 2024·0 cites·14 claims
- 0275US12245994B2Use of atovaquone and proguanil for treatment of gastrointestinal diseases and inflammationELEVAID THERAPEUTICS INC·Filed 2022·Granted Mar 11, 2025·0 cites·9 claims
- 0364US2025177323A1Use of atovaquone and proguanil for treatment of gastrointestinal diseases and inflammationELEVAID THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0462US2024245629A1Use of atovaquone and proguanil for reducing steroid use, all-cause hospitalization, or advanced therapy use in a subject diagnosed with inflammatory bowel disease, crohn's disease, or ulcerative colitisELEVAID THERAPEUTICS INC·Filed 2024·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ELEVAID THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →